Acumen Pharmaceuticals (ABOS) UBS Global Healthcare Conference 2024 summary

Company overview and recent progress

• Focuses on developing treatments for neurodegenerative diseases, primarily Alzheimer's, with a monoclonal antibody targeting toxic amyloid beta oligomers.

• Ongoing ALTITUDE-AD phase II study in 540 patients and a phase I study for a subcutaneous formulation of sabirnetug are progressing well.

• Cash position of $260 million as of end Q3, with runway into the first half of 2027, supporting completion of key clinical milestones.

• Enrollment for the phase II study is expected to complete in the first half of next year, with top-line results anticipated by the end of 2026.

• Phase I subcutaneous study will read out top-line results in Q1 2025, informing future development steps.

Industry landscape and market dynamics

• Recent years have seen significant progress in Alzheimer's treatment, with two approved anti-amyloid products and more in development.

• Market adoption has been slower than expected due to system readiness issues, including lack of infrastructure and reimbursement uncertainties.

• Infrastructure improvements are ongoing, expected to broaden patient access and support next-generation therapies.

• Anti-A beta strategies are expected to remain a cornerstone of Alzheimer's treatment, with potential for combination therapies in the future.

Clinical development and strategy

• ALTITUDE-AD phase II is designed as a randomized, double-blind, placebo-controlled study, with potential to serve as a pivotal study for registration.

• No interim analyses will be conducted in phase II to preserve registration eligibility and statistical integrity.

• Subcutaneous formulation is being developed to offer greater convenience and healthcare flexibility, with future integration options under consideration.

• Strategic flexibility includes potential for open-label extension, standalone phase IIa, or phase III integration for subcutaneous dosing.